Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model

Authors: Yunfei Li, Mingji Jin, Shuai Shao, Wei Huang, Feifei Yang, Wei Chen, Shenghua Zhang, Guimin Xia, Zhonggao Gao

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The small size of ultra-small nanoparticles makes them suitable for lymphatic delivery, and many recent studies have examined their role in anti-metastasis therapy. However, the anti-metastatic efficacy of small-sized nanocarriers loaded with taxanes such as docetaxel has not yet been investigated in malignant breast cancer.

Methods

We encapsulated docetaxel using poly(D,L-lactide)1300-b-(polyethylene glycol-methoxy)2000 (mPEG2000-b-PDLLA1300) to construct polymeric micelles with a mean diameter of 16.76 nm (SPM). Patient-like 4T1/4T1luc breast cancer models in Balb/c mice, with resected and unresected primary tumors, were used to compare the therapeutic efficacies of SPM and free docetaxel (Duopafei) against breast cancer metastasis using bioluminescent imaging, lung nodule examination, and histological examination.

Result

SPM showed similar efficacy to Duopafei in terms of growth suppression of primary tumors, but greater chemotherapeutic efficacy against breast cancer metastasis. In addition, lung tissue inflammation was decreased in the SPM-treated group, while many tumor cells and neutrophils were found in the Duopafei-treated group.

Conclusion

Small-sized mPEG2000-b-PDLLA1300 micelles could provide an enhanced method of docetaxel delivery in breast cancer metastasis, and may represent a valid chemotherapeutic strategy in breast cancer patients with resected primary tumors.
Appendix
Available only for authorised users
Literature
1.
Parker B, Sukumar S: Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biol Ther. 2003, 2 (1): 14-21.CrossRefPubMed
2.
Gong C, Yang B, Qian Z, Zhao X, Wu Q, Qi X, Wang Y, Guo G, Kan B, Luo F: Improving intraperitoneal chemotherapeutic effect and preventing postsurgical adhesions simultaneously with biodegradable micelles. Nanomedicine. 2012, 8 (6): 963-973. 10.1016/j.nano.2011.10.010.PubMed
3.
Kataoka K, Harada A, Nagasaki Y: Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2012, 47 (1): 113-131.CrossRef
4.
Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O: Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2007, 83 (5): 761-769.CrossRefPubMed
5.
Davis ME: Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008, 7 (9): 771-782. 10.1038/nrd2614.CrossRefPubMed
6.
Dobrovolskaia MA, McNeil SE: Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007, 2 (8): 469-478. 10.1038/nnano.2007.223.CrossRefPubMed
7.
Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil–based paclitaxel in women with breast cancer. J Clin Oncol. 2005, 23 (31): 7794-7803. 10.1200/JCO.2005.04.937.CrossRefPubMed
8.
Wong C, Stylianopoulos T, Cui J, Martin J, Chauhan VP, Jiang W, Popović Z, Jain RK, Bawendi MG, Fukumura D: Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci. 2011, 108 (6): 2426-2431. 10.1073/pnas.1018382108.CrossRefPubMedPubMedCentral
9.
10.
Volk LD, Flister MJ, Chihade D, Desai N, Trieu V, Ran S: Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia. 2011, 13 (4): 327-CrossRefPubMedPubMedCentral
11.
O’brien M, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback D, Tomczak P, Ackland S: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004, 15 (3): 440-449. 10.1093/annonc/mdh097.CrossRefPubMed
12.
Fang J, Nakamura H, Maeda H: The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011, 63 (3): 136-151. 10.1016/j.addr.2010.04.009.CrossRefPubMed
13.
Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG: Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2011, 12 (1): 39-50. 10.1038/nrc3180.CrossRefPubMed
14.
Peiris PM, Toy R, Doolittle E, Pansky J, Abramowski A, Tam M, Vicente P, Tran E, Hayden E, Camann A: Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano. 2012, 6 (10): 8783-8795. 10.1021/nn303833p.CrossRefPubMedPubMedCentral
15.
Chen SL, Iddings DM, Scheri RP, Bilchik AJ: Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin. 2006, 56 (5): 292-309. 10.3322/canjclin.56.5.292.CrossRefPubMed
16.
Tammela T, Saaristo A, Holopainen T, Ylä-Herttuala S, Andersson LC, Virolainen S, Immonen I, Alitalo K: Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med. 2011, 3 (69): 69ra11-69ra11.CrossRefPubMed
17.
Weinberg RA: The biology of cancer, vol. 255. 2007, New York: Garland Science
18.
Anderson C, Jacobson G, Bhatia S, Buatti JM: Atlas of Diagnostic Oncology. Int J Radiat Oncol Biol Phys. 2011, 81 (1): 314-314. 10.1016/j.ijrobp.2011.04.021.CrossRef
19.
Tang N, Du G, Wang N, Liu C, Hang H, Liang W: Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst. 2007, 99 (13): 1004-1015. 10.1093/jnci/djm027.CrossRefPubMed
20.
Qin L, Zhang F, Lu X, Wei X, Wang J, Fang X, Si D, Wang Y, Zhang C, Yang R: Polymeric micelles for enhanced lymphatic drug delivery to treat metastatic tumors. J Control Release. 2013, 171 (2): 133-142. 10.1016/j.jconrel.2013.07.005.CrossRefPubMed
21.
Rafi M, Cabral H, Kano M, Mi P, Iwata C, Yashiro M, Hirakawa K, Miyazono K, Nishiyama N, Kataoka K: Polymeric micelles incorporating (1, 2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J Control Release. 2012, 159 (2): 189-196. 10.1016/j.jconrel.2012.01.038.CrossRefPubMed
22.
Wei X, Wang Y, Zeng W, Huang F, Qin L, Zhang C, Liang W: Stability Influences the Biodistribution, Toxicity, and Anti-tumor Activity of Doxorubicin Encapsulated in PEG-PE Micelles in Mice. Pharm Res. 2012, 29 (7): 1977-1989. 10.1007/s11095-012-0725-5.CrossRefPubMed
23.
Bae YH, Yin H: Stability issues of polymeric micelles. J Control Release. 2008, 131 (1): 2-4. 10.1016/j.jconrel.2008.06.015.CrossRefPubMed
24.
Wang Y, Wang R, Lu X, Lu W, Zhang C, Liang W: Pegylated phospholipids-based self-assembly with water-soluble drugs. Pharm Res. 2010, 27 (2): 361-370. 10.1007/s11095-009-0029-6.CrossRefPubMed
25.
Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med. 1995, 332 (15): 1004-1014. 10.1056/NEJM199504133321507.CrossRefPubMed
26.
Miller KD, Sledge GW: Taxanes in the Treatment of Breast Cancer: A Prodigy Comes of Age. Cancer Invest. 1999, 17 (2): 121-136. 10.3109/07357909909011727.CrossRefPubMed
27.
Bhalla KN: Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003, 22 (56): 9075-9086. 10.1038/sj.onc.1207233.CrossRefPubMed
28.
CHABNER BA LONGODL: Cancer chemotherapy & biotherapy. Principles & practice. 2001
29.
Jones S: Head-to-head: docetaxel challenges paclitaxel. Eur J Cancer Suppl. 2006, 4 (4): 4-8. 10.1016/S1359-6349(06)80002-9.CrossRef
30.
Araque Arroyo P, Ubago Pérez R, Cancela Díez B, Fernández Feijóo MA, Hernández Magdalena J, Calleja Hernández MA: Controversies in the management of adjuvant breast cancer with taxanes: Review of the current literature. Cancer Treat Rev. 2011, 37 (2): 105-110. 10.1016/j.ctrv.2010.06.002.CrossRefPubMed
31.
Kim D-W, Kim S-Y, Kim H-K, Kim S-W, Shin S, Kim J, Park K, Lee M, Heo D: Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007, 18 (12): 2009-2014. 10.1093/annonc/mdm374.CrossRefPubMed
32.
Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH: In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 2001, 72 (1): 191-202.CrossRefPubMed
33.
Kim T-Y, Kim D-W, Chung J-Y, Shin SG, Kim S-C, Heo DS, Kim NK, Bang Y-J: Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004, 10 (11): 3708-3716. 10.1158/1078-0432.CCR-03-0655.CrossRefPubMed
34.
Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim S-B, Rha SY, Lee MY, Ro J: Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat. 2008, 108 (2): 241-250. 10.1007/s10549-007-9591-y.CrossRefPubMed
35.
Zhang X, Jackson JK, Burt HM: Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm. 1996, 132 (1): 195-206.CrossRef
36.
Liggins R, Burt H: Polyether–polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev. 2002, 54 (2): 191-202. 10.1016/S0169-409X(02)00016-9.CrossRefPubMed
37.
Pulaski BA, Ostrand‒Rosenberg S: Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001, 20.22. 21-20.22. 16.
38.
Eckhardt BL, Francis PA, Parker BS, Anderson RL: Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012, 11 (6): 479-497. 10.1038/nrd2372.CrossRefPubMed
39.
Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K: Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery. 2013, 153 (6): 771-778. 10.1016/j.surg.2013.02.002.CrossRefPubMedPubMedCentral
40.
Xiao L, Xiong X, Sun X, Zhu Y, Yang H, Chen H, Gan L, Xu H, Yang X: Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. Biomaterials. 2011, 32 (22): 5148-5157. 10.1016/j.biomaterials.2011.03.071.CrossRefPubMed
41.
Luo Y, Ling Y, Guo W, Pang J, Liu W, Fang Y, Wen X, Wei K, Gao X: Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release. 2010, 147 (2): 278-288. 10.1016/j.jconrel.2010.07.108.CrossRefPubMed
42.
Tao K, Fang M, Alroy J, Sahagian GG: Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008, 8 (1): 228-10.1186/1471-2407-8-228.CrossRefPubMedPubMedCentral
43.
Jenkins DE, Yu S-F, Hornig YS, Purchio T, Contag PR: In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3 M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis. 2003, 20 (8): 745-756.CrossRefPubMed
44.
Sheikh AY, Lin SA, Cao F, Cao Y, Van der Bogt KE, Chu P, Chang CP, Contag CH, Robbins RC, Wu JC: Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells. 2007, 25 (10): 2677-2684. 10.1634/stemcells.2007-0041.CrossRefPubMedPubMedCentral
45.
46.
Aslakson CJ, Miller FR: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52 (6): 1399-1405.PubMed
47.
Pulaski BA, Smyth MJ, Ostrand-Rosenberg S: Interferon-γ-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 2002, 62 (15): 4406-4412.PubMed
48.
Harris J, Morrow M, Norton L: Malignant tumors of the breast. Cancer Principles Pract Oncol. 1997, 2: 1557-1616.
49.
Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J: miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009, 4 (9): e7181-10.1371/journal.pone.0007181.CrossRefPubMedPubMedCentral
50.
Harris J, Morrow M, Norton L: Malignant tumors of the breast. Cancer: Principles and Practice of Oncology Philadelphia, PA, Lippincott. 1997, 1557-1616.
51.
Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009, 182 (8): 4499-4506. 10.4049/jimmunol.0802740.CrossRefPubMedPubMedCentral
52.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009, 30 (7): 1073-1081. 10.1093/carcin/bgp127.CrossRefPubMed
Metadata
Title
Small-sized polymeric micelles incorporating docetaxel suppress distant metastases in the clinically-relevant 4T1 mouse breast cancer model
Authors
Yunfei Li
Mingji Jin
Shuai Shao
Wei Huang
Feifei Yang
Wei Chen
Shenghua Zhang
Guimin Xia
Zhonggao Gao
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-329

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Ethnic differences in timely adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand: a cohort study

Research article

Oxidative stress in susceptibility to breast cancer: study in Spanish population

Research article

Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

Research article

Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample

Research article

Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines

Study protocol

Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits